The OHSU Knight Cancer Institute Data and Safety Monitoring Plan (DSMP) follows the policy of the National Cancer Institute for data and safety monitoring of investigator-initiated clinical trials. The purpose of the DSMP is to insure the safety of study participants, the validity of research data and the appropriate termination of studies for which significant benefits or risks have been uncovered or when it appears that the trial cannot be concluded successfully. We also assert that monitoring is a critical instrument for human subjects protection, as it provides investigators direct feedback about their research practices and identifies areas for improvement that can be identified in no other way. It is one of the only mechanisms by which the DSMC can ensure that the study is being conducted in accordance with the IRB and CRRC-approved protocol. When performed in a quality assurance fashion with an educational rather than policing focus, objective monitoring of actual protocol procedures is also one of the most important tools we have to educate investigators on the practical aspects of human subjects protections. Examination of actual research records is the only to way to uncover certain potentially serious compliance issues, such as improperly documented consent, failing to meet eligibility requirements or failure to report adverse events.
The purpose of the DSMP is to insure the safety of study participants, the validity of research data and the appropriate termination of studies for which significant benefits or risks have been uncovered or when it appears that the trial cannot be concluded successfully.
|Chen, Yiyi; Chen, Zunqiu; Mori, Motomi (2016) A new statistical decision rule for single-arm phase II oncology trials. Stat Methods Med Res 25:118-32|
|Pati, Shibani; Potter, Daniel R; Baimukanova, Gyulnar et al. (2016) Modulating the endotheliopathy of trauma: Factor concentrate versus fresh frozen plasma. J Trauma Acute Care Surg 80:576-84; discussion 584-5|
|Coleman, Daniel J; Van Hook, Kathryn; King, Carly J et al. (2016) Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor. Oncotarget 7:40690-40703|
|Tsikitis, Vassiliki L; Potter, Amiee; Mori, Motomi et al. (2016) MicroRNA Signatures of Colonic Polyps on Screening and Histology. Cancer Prev Res (Phila) 9:942-949|
|Wiedmeier, Julia Erin; Kato, Catherine; Zhang, Zhenzhen et al. (2016) Clonal hematopoiesis as determined by the HUMARA assay is a marker for acquired mutations in epigenetic regulators in older women. Exp Hematol 44:857-865.e5|
|Young, John I; Mongoue-Tchokote, Solange; Wieghard, Nicole et al. (2016) Treatment and Survival of Small-bowel Adenocarcinoma in the United States: A Comparison With Colon Cancer. Dis Colon Rectum 59:306-15|
|Goodspeed, Andrew; Heiser, Laura M; Gray, Joe W et al. (2016) Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics. Mol Cancer Res 14:3-13|
|Ebrahim, Seham; Avenarius, Matthew R; Grati, M'hamed et al. (2016) Stereocilia-staircase spacing is influenced by myosin III motors and their cargos espin-1 and espin-like. Nat Commun 7:10833|
|Cambronne, Xiaolu A; Stewart, Melissa L; Kim, DongHo et al. (2016) Biosensor reveals multiple sources for mitochondrial NADâº. Science 352:1474-7|
|Zhang, Zhenzhen; Garzotto, Mark; Beer, Tomasz M et al. (2016) Effects of Ï‰-3 Fatty Acids and Catechins on Fatty Acid Synthase in the Prostate: A Randomized Controlled Trial. Nutr Cancer 68:1309-1319|
Showing the most recent 10 out of 188 publications